• Home
  •  / Genocea Biosciences

Genocea Biosciences

OverviewSuggest Edit

Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company is using its proprietary ATLAS antigen identification platform to build a pipeline of immunotherapies that currently includes its lead candidate, GEN-003, an immunotherapy for genital herpes, and GEN-009, its first neoantigen cancer vaccine.

TypePublic
Founded2006
HQCambridge, MA, USMap
Websitegenocea.com
Employee Ratings3.6More
Overall CultureDMore
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)59(-3%)
Share Price (Jan 2021)$3 (-6%)
Cybersecurity ratingCMore

Key People/Management at Genocea Biosciences

Girish Aakalu

Girish Aakalu

Chief Business Officer
Chip Clark

Chip Clark

President and Chief Executive Officer
Diantha Duvall

Diantha Duvall

Chief Financial Officer
Jessica Baker Flechtner

Jessica Baker Flechtner

Chief Scientific Officer
Tom Davis

Tom Davis

Chief Medical Officer
Narinder Singh

Narinder Singh

SVP, Pharmaceutical Sciences and Manufacturing
Show more

Genocea Biosciences Office Locations

Genocea Biosciences has an office in Cambridge
Cambridge, MA, US (HQ)
100 Acorn Park Dr
Show all (1)

Genocea Biosciences Financials and Metrics

Genocea Biosciences Revenue

USD

Revenue (Q3, 2020)

453.0k

Net income (Q3, 2020)

(4.6m)

EBIT (Q3, 2020)

(10.7m)

Market capitalization (22-Jan-2021)

156.5m

Closing stock price (22-Jan-2021)

3.0

Cash (30-Sept-2020)

87.6m

EV

82.6m
Genocea Biosciences's current market capitalization is $156.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

9.7m14.0m15.4m13.4m14.3m12.0m

R&D expense

23.7m28.0m34.6m39.2m25.2m27.0m

Operating expense total

33.5m42.0m50.1m52.6m39.5m39.0m

EBIT

(33.2m)(41.4m)(48.2m)(55.3m)(39.5m)(39.0m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

906.0k453.0k

General and administrative expense

2.0m2.4m2.8m3.4m3.2m3.6m3.9m4.0m3.6m3.6m3.6m3.8m3.1m4.5m4.1m3.0m3.2m2.8m3.4m3.5m3.6m

R&D expense

4.4m4.6m6.1m8.5m7.0m6.1m7.3m6.7m8.8m9.7m11.4m10.2m7.3m5.3m6.4m6.5m6.8m6.8m10.0m8.6m7.5m

Operating expense total

6.4m6.9m9.0m11.9m10.1m9.7m11.3m10.7m12.4m13.4m15.0m16.5m10.4m9.8m10.5m9.5m10.1m9.6m13.4m12.1m11.2m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

20.1m17.3m27.4m12.3m26.4m40.1m

Prepaid Expenses

963.0k865.0k808.0k696.0k1.5m

Current Assets

48.0m95.2m64.3m13.1m27.1m41.6m

PP&E

2.0m4.1m4.9m3.5m2.6m2.6m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

65.8m32.1m25.1m57.5m49.6m42.8m37.7m18.3m26.4m34.1m35.2m22.0m51.2m44.2m34.5m29.0m58.7m46.6m26.5m22.1m87.6m

Prepaid Expenses

944.0k1.1m1.3m1.1m770.0k883.0k1.6m1.3m950.0k1.4m1.7m1.3m1.4m1.3m1.9m1.5m1.1m1.3m2.6m2.6m2.7m

Current Assets

66.9m60.3m53.5m85.6m75.4m98.5m97.5m87.3m76.4m50.1m37.0m23.3m52.6m45.5m36.4m30.9m59.7m47.9m29.1m24.7m90.3m

PP&E

814.0k1.1m1.9m2.1m2.6m3.7m4.8m4.9m5.0m4.8m4.9m4.0m3.2m3.1m2.8m2.5m2.8m2.9m2.5m2.5m3.0m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(35.3m)(42.5m)(49.6m)(56.7m)(27.8m)(38.9m)

Depreciation and Amortization

469.0k1.1m1.8m1.5m1.1m1.1m

Accounts Payable

516.0k(1.4m)1.2m491.0k(2.1m)(1.1m)

Cash From Operating Activities

(27.6m)(38.4m)(41.8m)(47.6m)(41.2m)(37.7m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(7.3m)(14.5m)(23.6m)(12.1m)(22.4m)(32.2m)(9.8m)(20.8m)(33.5m)(13.7m)(29.1m)(46.0m)(15.9m)(20.3m)(28.2m)(15.6m)(22.1m)(29.6m)(12.9m)(24.2m)(28.7m)

Depreciation and Amortization

78.0k160.0k298.0k180.0k391.0k661.0k361.0k828.0k1.3m449.0k878.0k1.2m270.0k543.0k815.0k272.0k550.0k825.0k276.0k556.0k867.0k

Accounts Payable

(1.1m)(1.0m)(671.0k)(143.0k)

Cash From Operating Activities

(6.5m)(13.0m)(19.2m)(10.7m)(20.1m)(28.4m)(10.2m)(19.9m)(30.1m)(14.7m)(28.0m)(39.4m)(13.1m)(23.4m)(33.1m)(10.3m)(17.9m)(28.7m)(13.8m)(23.7m)(32.0m)
show all
USDQ1, 2014

Debt/Equity

0.2 x

Debt/Assets

0.1 x

Financial Leverage

1.2 x
Show all financial metrics

Genocea Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

Learn more about our premium products
SecurityScorecard logo

Genocea Biosciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Genocea Biosciences Online and Social Media Presence

Genocea Biosciences's Trends

Embed Graph

Genocea Biosciences Company Culture

  • Overall Culture

    D

    59/100

  • CEO Rating

    F

    50/100

  • Compensation

    C+

    70/100

Learn more on Comparably

Genocea Biosciences News and Updates

July 23, 2020

Thinking about buying stock in Genocea Biosciences, Sunworks Inc, Onconova Therapeutics, United Airlines, or General Electric?

NEW YORK, July 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNCA, SUNW, ONTX, UAL, and GE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
June 03, 2019

Thinking about buying stock in Aurora Cannabis, Cypress Semiconductor, Delmar Pharmaceuticals, Genocea Biosciences, or Stellar Biotech?

NEW YORK, June 3, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, CY, DMPI, GNCA, and SBOT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
June 03, 2019

Genocea Biosciences shares rocket 101% after positive data on cancer vaccine

Genocea Biosciences shares rocket 101% after positive data on cancer vaccine
June 03, 2019

Genocea Biosciences shares rocket 101% after biotech announces positive data from early-stage trial of cancer vaccine

Shares of Genocea Biosciences Inc. surged 101% in premarket trade Monday after the biotech announced promising data from an early-stage clinical trial of its lead drug candidate, a personalized cancer vaccine. Genocea's vaccine, called GEN-009, uses neoantigens -- antigens corresponding to tumor mu…
May 23, 2019

Thinking about buying stock in Avon Products, Genocea Biosciences, L Brands, Netshoes, or Obalon Therapeutics?

NEW YORK, May 23, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVP, GNCA, LB, NETS, and OBLN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
February 14, 2019

Genital Herpes Market Insights, Epidemiology and Market Forecasts Report 2019 Featuring Novartis, GlaxoSmithKline, Genocea Biosciences, AiCuris & Maruho

DUBLIN, Feb. 14, 2019 /PRNewswire/ -- The "Genital Herpes - Market Insights, Epidemiology and Market Forecast-2028" report has been added to ResearchAndMarkets.com's offering. The global market of Genital Herpes was estimated to be USD 1,211.3 million in 2018. Genital Herpes - Market...
Show more

Genocea Biosciences Blogs

October 22, 2020

Genocea to Host Third Quarter 2020 Corporate Update Conference Call & Webcast

CAMBRIDGE, Mass. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2020 financial results and corporate update conference call and live audio webcast
October 14, 2020

Genocea Announces Upcoming Data Presentations at Virtual SITC 2020

Genocea Announces Upcoming Data Presentations at Virtual SITC 2020 Content Import Wed, 10/14/2020 - 17:22 Genocea Announces Upcoming Data Presentations at Virtual SITC 2020 October 14, 2020 at 5:22 PM EDT This release is a backfill from a News Wire …
July 30, 2020

Genocea to Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine GEN-009 in Combination with Checkpoint Inhibitors

Genocea to Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine GEN-009 in Combination with Checkpoint Inhibitors Content Import Thu, 07/30/2020 - 07:03 Genocea to Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine GEN-009 in Combination with Check…
July 22, 2020

Genocea Announces Private Placement Financing of Up to $80 Million

Genocea Announces Private Placement Financing of Up to $80 Million Content Import Wed, 07/22/2020 - 09:03 Genocea Announces Private Placement Financing of Up to $80 Million July 22, 2020 at 9:02 AM EDT This release is a backfill from a News Wire …
July 20, 2020

Genocea Biosciences Provides Clinical Update

CAMBRIDGE, Mass. , July 20, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced updates to its clinical programs, the neoantigen vaccine GEN-009 and the neoantigen cell therapy,
July 16, 2020

Genocea to Host Second Quarter 2020 Corporate Update Conference Call & Webcast

Genocea to Host Second Quarter 2020 Corporate Update Conference Call & Webcast Content Import Thu, 07/16/2020 - 08:01 Genocea to Host Second Quarter 2020 Corporate Update Conference Call & Webcast July 16, 2020 at 8:00 AM EDT This release is a backfill…
Show more

 Genocea Biosciences Frequently Asked Questions

  • When was Genocea Biosciences founded?

    Genocea Biosciences was founded in 2006.

  • Who are Genocea Biosciences key executives?

    Genocea Biosciences's key executives are Girish Aakalu, Chip Clark and Diantha Duvall.

  • How many employees does Genocea Biosciences have?

    Genocea Biosciences has 59 employees.

  • Who are Genocea Biosciences competitors?

    Competitors of Genocea Biosciences include Emtora Biosciences, Northwest Biotherapeutics and Merrimack Pharmaceuticals.

  • Where is Genocea Biosciences headquarters?

    Genocea Biosciences headquarters is located at 100 Acorn Park Dr, Cambridge.

  • Where are Genocea Biosciences offices?

    Genocea Biosciences has an office in Cambridge.

  • How many offices does Genocea Biosciences have?

    Genocea Biosciences has 1 office.